Principal Financial Group Inc. Has $178.05 Million Holdings in Boston Scientific Co. (NYSE:BSX)

Principal Financial Group Inc. decreased its holdings in shares of Boston Scientific Co. (NYSE:BSX - Free Report) by 0.8% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,993,444 shares of the medical equipment provider's stock after selling 16,997 shares during the quarter. Principal Financial Group Inc. owned 0.14% of Boston Scientific worth $178,054,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also modified their holdings of BSX. Creative Planning grew its holdings in shares of Boston Scientific by 7.7% during the third quarter. Creative Planning now owns 204,208 shares of the medical equipment provider's stock valued at $17,113,000 after buying an additional 14,663 shares in the last quarter. Global Retirement Partners LLC grew its holdings in shares of Boston Scientific by 11.5% during the third quarter. Global Retirement Partners LLC now owns 4,370 shares of the medical equipment provider's stock valued at $366,000 after buying an additional 449 shares in the last quarter. Stratos Wealth Advisors LLC grew its holdings in shares of Boston Scientific by 8.9% during the third quarter. Stratos Wealth Advisors LLC now owns 6,419 shares of the medical equipment provider's stock valued at $538,000 after buying an additional 522 shares in the last quarter. Blue Trust Inc. grew its stake in Boston Scientific by 91.6% in the third quarter. Blue Trust Inc. now owns 10,492 shares of the medical equipment provider's stock valued at $808,000 after purchasing an additional 5,017 shares in the last quarter. Finally, Capital Investment Advisors LLC purchased a new position in Boston Scientific in the third quarter valued at about $217,000. Hedge funds and other institutional investors own 89.07% of the company's stock.

Boston Scientific Stock Down 0.9 %

BSX stock traded down $0.93 during trading hours on Friday, reaching $104.44. 5,512,880 shares of the stock were exchanged, compared to its average volume of 6,033,932. The company has a market cap of $154.12 billion, a price-to-earnings ratio of 83.55, a PEG ratio of 2.79 and a beta of 0.80. The firm's 50-day moving average is $97.98 and its 200-day moving average is $89.27. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.08 and a quick ratio of 1.02. Boston Scientific Co. has a 12 month low of $65.52 and a 12 month high of $107.17.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $0.70 earnings per share for the quarter, beating the consensus estimate of $0.65 by $0.05. Boston Scientific had a return on equity of 17.80% and a net margin of 11.07%. On average, equities research analysts expect that Boston Scientific Co. will post 2.85 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on the company. Piper Sandler boosted their target price on Boston Scientific from $95.00 to $115.00 and gave the company an "overweight" rating in a research note on Monday, February 3rd. Raymond James boosted their price target on Boston Scientific from $119.00 to $122.00 and gave the company a "strong-buy" rating in a research note on Thursday, February 6th. Truist Financial upped their price objective on Boston Scientific from $100.00 to $110.00 and gave the company a "buy" rating in a research note on Wednesday, December 18th. Mizuho increased their price target on Boston Scientific from $100.00 to $110.00 and gave the stock an "outperform" rating in a research report on Thursday, October 24th. Finally, Canaccord Genuity Group increased their price target on Boston Scientific from $98.00 to $101.00 and gave the stock a "buy" rating in a research report on Monday, December 9th. Two investment analysts have rated the stock with a hold rating, twenty-one have assigned a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $107.39.

Insider Activity at Boston Scientific

In related news, EVP Arthur C. Butcher sold 14,010 shares of the firm's stock in a transaction dated Monday, November 25th. The shares were sold at an average price of $89.27, for a total value of $1,250,672.70. Following the completion of the sale, the executive vice president now directly owns 978 shares in the company, valued at approximately $87,306.06. This trade represents a 93.47 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Wendy Carruthers sold 6,983 shares of the firm's stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $90.78, for a total transaction of $633,916.74. Following the completion of the sale, the executive vice president now owns 29,308 shares of the company's stock, valued at $2,660,580.24. This trade represents a 19.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 153,640 shares of company stock worth $15,718,289. Insiders own 0.50% of the company's stock.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.